Pasithea Therapeutics

Pasithea Therapeutics EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is 2.33. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -0.92 — a change of -351.87% (higher).

EV/OCF

2.33

YoY

-351.87%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Pasithea Therapeutics is 2025 2.33 . EV/OCF (Enterprise Value to Operating Cash Flow) of Pasithea Therapeutics was 2024 -0.92 . It decreases by -351.87% higher compared to the previous year.

The Pasithea Therapeutics EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2020
-504.96 USD
Jan 1, 2021
10.46 USD
Jan 1, 2022
0.94 USD
Jan 1, 2023
-0.26 USD
Jan 1, 2024
-0.92 USD
Jan 1, 2025
2.33 USD
The Pasithea Therapeutics EV/OCF history
YEAREV/OCFYoY
2.33-351.87%
-0.92+251.15%
-0.26-128.12%
0.94-91.06%
10.46-102.07%
-504.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Pasithea Therapeutics is 2.33 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Pasithea Therapeutics changed from -0.92 to 2.33, representing a -351.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Pasithea Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics